FDMT - 4D Molecular Therapeutics, Inc.
About 4D Molecular Therapeutics, Inc. (https://www.4dmoleculartherapeutics.com)
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| David H. Kirn | Co-Founder, President, CEO & Director | 1963 | $1,228,593 USD |
| Fariborz Kamal | Chief Technical Advisor | 1963 | $892,868 USD |
| Theresa Janke | Co-Founder & Chief of Staff | 1975 | $652,315 USD |
| Noriyuki Kasahara | Chief Scientific Advisor & Member of Scientific Advisory Board | 1963 | $201,288 USD |
| John F. Milligan | Executive Chairman | 1961 | $150,000 USD |
| Kristian Humer | CFO and Principal Financial & Accounting Officer | 1976 | $116,247 USD |
| An Song | Chief Translational Medicine Advisor | – | – |
| Ashoo Gupta | Principal Accounting Officer & Principal Financial Officer | 1976 | – |
| Julian Pei | Head of Investor Relations & Corporate Finance | – | – |
| Katy Barglow | Chief Technical Officer | – | – |
| Scott Bizily | Chief Legal Officer & Corporate Secretary | 1972 | – |